Correspondence highlights crucial questions regarding optimal management of hyperuricemia in gout treatment.
I appreciate the letter by Drs. Therán-León and Otero-Rueda¹ that further discusses the key issues from the editorial,² in depth. They raised 2 critical questions: (1) How can the care be improved from the current poor quality of care for long-term hyperuricemia management for gout in primary care to optimal gout care? (2) Who will provide the treat-to-target (T2T) approach with the use of urate-lowering therapy (ULT) in primary care, where the majority of patients with gout are managed?
No takes yet. Share an insight, caveat, or question.
Jasvinder A. Singh (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: